Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIBP-A18
- Development stage
- Phase 1
- Lead developer
- Shanghai Institute of Biological Products
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SIBP-A18 is an **antibody-drug conjugate (ADC)** targeting claudin 18.2 (CLDN18.2) and DNA topoisomerase I (TOP1). It is being developed for the treatment of advanced malignant solid tumors, with a primary focus on evaluating its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor efficacy in Phase 1 clinical trials. SIBP-A18's mechanism involves specific inhibition of CLDN18.2, a tight junction protein selectively expressed in various cancers, and inhibition of TOP1 to induce DNA damage in tumor cells. The developer is the Shanghai Institute of Biological Products. The clinical trial is designed with dose escalation, dose expansion, and indication expansion stages, with intravenous administration at dosages ranging from 1.0 to 8.0 mg/kg[1][2][5][7].
- Brand names
- SIBP-A18SIBP-A-18SIBP-A 18
- Other names
- SIBP-A18SIBP-A-18SIBP-A 18
02
Targets
Claudin 18.2TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on SIBP-A18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIBP-A18.